HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shenzhen Creality 3D Technology (PHIP Updates) - The Business and the Outlook

Pre-IPO Liuliumei Co., Ltd. (PHIP Updates) - Some Points Worth the Attention

Pre-IPO SpaceX - About the Business, the Concerns and Thoughts on Valuation

Pre-IPO Axbio International - Has the Potential to Be a Game Changer in Molecular Testing Market

Pre-IPO Guangdong CHJ Industry - The Business Model, the Concerns and the Outlook

3SBio (1530 HK) Plans to Spin-Off and List Mandi in HK - Thoughts on The "Implied" IPO Price

Equity Capital Markets

Lupeng Pharmaceutical / Equity Capital Markets

<ul>
<li>The product that best represents Lupeng's breakthrough proposition from numerous pipelines would undoubtedly be LP-168, whose unique development path has the opportunity to gain market attention. </li>
<li>How much market LP-168 is able to seize from existing players is highly uncertain. Since LP-108/LP-118 are in early clinical stage, there's a possibility of R&amp;D failure in the future.</li>
<li>Post-Money valuation after Series B Financing was US$311.25mn. Since Lupeng has no commercialized products on the market, its valuation would be lower than peers such as BeiGene, Innocare and Ascentage.</li>
</ul>


The product that best represents Lupeng's breakthrough proposition from numerous pipelines would undoubtedly be LP-168, whose unique development path has the opportunity to gain market attention. 
How much market LP-168 is able to seize from existing players is highly uncertain. Since LP-108/LP-118 are in early clinical stage, there's a possibility of R&amp;D failure in the future.
Post-Money valuation after Series B Financing was US$311.25mn. Since Lupeng has no commercialized products on the market, its valuation would be lower than peers such as BeiGene, Innocare and Ascentage.


Pre-IPO Lupeng Pharmaceutical - Unique Pipeline May Not Guarantee the Commercialization Outlook